Table 2.
Characterization of the cohort of patients with systemic sclerosis regarding S1PR–aAb.
| S1PR1–aAb | S1PR2–aAb | S1PR3–aAb | |||||
|---|---|---|---|---|---|---|---|
| SSc n=158 | positive* n=27 (17.1%) | negative n=131 (82.9%) | positive* n=30 (19%) | negative n=128 (81%) | positive* n=34 (21.5%) | negative n=124 (78.5%) | |
| Cutanous manifestation | |||||||
| Limited, n (%) | 91 (58%) | 23 (85.2%) | 68 (52.3%) | 14 (48.3%) | 77 (60.2%) | 13 (39.4%) | 78 (62.9%) |
| Diffuse, n (%) | 59 (38%) | 4 (14.8%) | 55 (42.3%) | 14 (48.3%) | 45 (35.2%) | 19 (57.6%) | 40 (32.3%) |
| Sine scleroderma, n (%) | 7 (4%) | 0 (0%) | 7 (5.4%) | 1 (3.4%) | 6 (4.7%) | 1 (3.0%) | 6 (4.8%) |
| mRSS, median (range) |
6 (0–39) | 4 (0–24) | 6 (0–39) | 5 (0–27) | 6 (0–39) | 5 (0–27) | 6 (0–39) |
| Pulmonary & cardiac involvement | |||||||
| NTproBNP [ng/L], median (range) | 206 (5–19066) | 296 (46–4884) | 196 (5–19066) | 135 (5–19066) | 235 (29–14414) | 135 (5–4884) | 242 (29–19066) |
| PAH, n (%) | 58 (37%) | 9 (33.3%) | 49 (37.4%) | 15 (50%) | 43 (33.6%) | 16 (47.1%) | 42 (33.9%) |
| ILD, n (%) | 75 (48%) | 11 (40.7%) | 64 (49.6%) | 17 (60.7%) | 58 (45.3%) | 23 (71.9%) | 52 (41.9%) |
| Autoantibodies** | |||||||
| anti-topoisomerase-1 (Scl70) Ab, n (%) | 50 (33%) | 4 (15.4%) | 46 (36.2%) | 11 (39.3%) | 39 (31.2%) | 16 (48.5%) | 34 (28.3%) |
| anti-RNA-Pol-III Ab (ARA), n (%) | 13 (8%) | 2 (7.4%) | 11 (8.7%) | 2 (7.4%) | 11 (8.7%) | 4 (12.5%) | 9 (7.4%) |
| anti-centromere-CENP-B Ab, n (%) | 63 (41.4%) | 21 (75%) | 42 (33.6%) | 11 (40.7%) | 52 (41.6%) | 9 (29.0%) | 54 (44.6%) |
| anti-citrullinated-peptide Ab, n (%)*** | 30 (54.5%) | 6 (66.7%) | 24 (52.2%) | 10 (71.4%) | 20 (48.8%) | 8 (53.3%) | 22 (55%) |
Missing values were excluded from the calculation; mRSS, modified Rodnan-Skin-Score; ILD, interstitial lung disease; *P75+1.5xIQR, **all were antinuclear Ab (ANA) positive, ***positive: ≥7 U/ml.